Cargando…

Revisiting checkpoint inhibitors for myeloma: maintenance after stem cell transplant

Multiple myeloma is a hematologic malignancy of plasma cells that manifests with bone marrow tumors causing lytic bone lesions. Autologous stem cell transplantation (ASCT) after high-dose chemotherapy and followed by prolonged maintenance therapy with lenalidomide (LEN) is an effective standard-of-c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meermeier, Erin W., Bergsagel, P. Leif
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927926/ https://www.ncbi.nlm.nih.gov/pubmed/36787254 http://dx.doi.org/10.1172/JCI167346

Ejemplares similares

Checkpoint inhibitors and myeloma: promises, deadlocks and new directions
por: Bertamini, Luca, et al.
Publicado: (2020)

A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients.
por: Belch, A., et al.
Publicado: (1988)

Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup
por: Wiedmeier-Nutor, Julia Erin, et al.
Publicado: (2022)

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB
por: Demchenko, Yulia N., et al.
Publicado: (2014)

FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation
por: Blackmon, Amanda, et al.
Publicado: (2022)

The gut microbiota and immune checkpoint inhibitors
por: Humphries, Audrey, et al.
Publicado: (2018)

Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
por: Bird, Sarah A., et al.
Publicado: (2020)

Immune checkpoint inhibitor-related acral vasculitis
por: Comont, Thibault, et al.
Publicado: (2018)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Identification of PIKfyve kinase as a target in multiple myeloma
por: de Campos, Cecilia Bonolo, et al.
Publicado: (2020)

FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
por: Pulte, Elizabeth Dianne, et al.
Publicado: (2018)

Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco‐economic assessment
por: Uyl‐de Groot, Carin A., et al.
Publicado: (2020)

Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors
por: Mundra, Vatsala, et al.
Publicado: (2023)

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology
por: Jardim, Denis L., et al.
Publicado: (2018)

Antibiotic therapy and outcome from immune-checkpoint inhibitors
por: Pinato, David J., et al.
Publicado: (2019)

COVID-19 and immune checkpoint inhibitors: initial considerations
por: Sullivan, Ryan J, et al.
Publicado: (2020)

P1376: LENALIDOMIDE–BASED MAINTENANCE AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT FOR PATIENTS WITH HIGH RISK MULTIPLE MYELOMA
por: Pasvolsky, O., et al.
Publicado: (2022)

Post‐hematopoietic stem cell transplantation relapse: Role of checkpoint inhibitors
por: Roshandel, Elham, et al.
Publicado: (2022)

Mesenchymal Stem Cells for Coronavirus (COVID-19)-Induced Pneumonia: Revisiting the Paracrine Hypothesis with New Hopes?
por: Öztürk, Selçuk, et al.
Publicado: (2020)

Immune checkpoint inhibitors for multiple myeloma immunotherapy
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation
por: Fostier, Karel, et al.
Publicado: (2018)

P1303: DARATUMUMAB-BASED MAINTENANCE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AFTER SALVAGE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Pasvolsky, Oren, et al.
Publicado: (2023)

P1671: CARFILZOMIB-DEXAMETHASONE MAINTENANCE HAMPERS RECOVERY AFTER SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
por: Nielsen, Lene Kongsgaard, et al.
Publicado: (2023)

Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?
por: Dillman, Robert O.
Publicado: (2016)

Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity
por: Lee, Karla A, et al.
Publicado: (2020)

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
por: Akhuba, Liia, et al.
Publicado: (2023)

Revisiting regulatory T cells for stroke therapy
por: Lee, Juneyoung, et al.
Publicado: (2022)

UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression
por: Hussain, Sajjad, et al.
Publicado: (2015)

Immune checkpoint inhibitors: here to stay
por: Carvalho, Filomena Marino, et al.
Publicado: (2023)

Efficacy of PD-1 checkpoint inhibitor therapy in melanoma and beyond: are peripheral T cell phenotypes the key?
por: Flaherty, Katie R, et al.
Publicado: (2023)

Post-Transplant Maintenance Treatment Options in Multiple Myeloma
por: Karam, Dhauna, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
por: Belluomini, Lorenzo, et al.
Publicado: (2019)

Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors
por: Bersanelli, Melissa
Publicado: (2020)

How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases?
por: Minami, Yasunori, et al.
Publicado: (2022)

Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
por: Papavassiliou, Kostas A., et al.
Publicado: (2023)

Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer
por: Yu, Peter Paul, et al.
Publicado: (2019)

Revisit the signatures of γδ T cells in hepatocellular carcinoma
por: Gao, Yanan, et al.
Publicado: (2022)

PB2033: INFLUENCE OF INDUCTION THERAPY WITH LENALIDOMIDE ON MAINTENANCE THERAPY AND PROGNOSIS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
por: Sun, Q., et al.
Publicado: (2022)

Incidental findings in population imaging revisited
por: Bunnik, Eline M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ag9ccv2m1l71ntfafca60b5se6